International technology group integrating R & D, production and sales.

  • International Business

The acquisition of Miacalcic from Novartis enables NT Pharma to strategically enter the field of orthopaedic treatment, enrich its product portfolio, and enjoy a long-term growth potential.

business covers major countries in Asia Pacific regions including Thailand, Vietnam, Singapore, Malaysia, Hong Kong, Taiwan, Philippines, Indonesia, Australia, New Zealand .   For the rest of the territories, Mexico, Brazil and Egypt will later bec.

Except China & HKG, NTP has set up local partnership network to develop these major market. With the fundamental core services of warehousing and distribution, local sales and promotional activities will be implemented.  Brand planning and key opinion leaders management will be the long term objectives which undoubtedly are valuable resources for our regional academic events.

The annual revenue generated by the franchise business is approximately US$ 5 million.

Miacalcic is presented in two formulations, injection and nasal spray. The brand will remain its European identity. Both formulations will continue to be manufactured by NT Pharma manufacturing partners in Switzerland, France and Germany.

Miacalcic's wide sales network will help NT Pharma to further expand to markets outside of China, as well as lay a foundation for the Group's other products to enter the international marketplace.